57.99 -0.73 (-1.24%)
Pre-Market: 8:54AM EDT
|Bid||57.50 x 200|
|Ask||58.50 x 200|
|Day's Range||57.83 - 59.36|
|52 Week Range||45.42 - 99.45|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 1, 2018 - May 7, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||86.55|
Short interest is moderately high for CLVS with between 10 and 15% of shares outstanding currently on loan. This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on January 29.
Clovis Oncology, Inc. announced today that the Company has received a Notice of Allowance from the United States Patent and Trademark Office in United States Patent Application 14/828,065 with claims directed to high dosage strength rucaparib camsylate formulations.
Clovis Oncology, Inc. today announced that Patrick J. Mahaffy, Chief Executive Officer and President, will present at the Barclays Global Healthcare Conference on Thursday, March 15, 2018 at 8:00 AM Eastern Time.
NEW YORK, March 07, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
NEW YORK, NY / ACCESSWIRE / February 28, 2018 / U.S. markets dropped for the first time in four sessions on Tuesday as comments made by new Federal Reserve Chairman Jerome Powell hinted interest rates ...
Exelixis and Clovis shares diverged Tuesday after each reported lackluster sales of their biggest cancer drugs in the fourth quarter.
Clovis (CLVS) witnesses narrower year-over-year loss in the fourth quarter. However, the company's revenues miss estimates. Rubraca sales lower.
Index (PMI) data, output in the Healthcare sector is rising. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way.
On a per-share basis, the Boulder, Colorado-based company said it had a loss of $1.04. Losses, adjusted for non-recurring gains, were $1.27 per share. The results exceeded Wall Street expectations. The ...
Clovis Oncology, Inc. reported financial results for the quarter and year ended December 31, 2017, and provided an update on the Company’s clinical development programs and regulatory and commercial outlook for 2018.
NEW YORK, NY / ACCESSWIRE / February 26, 2018 / Clovis Oncology, Inc. (NASDAQ: CLVS ) will be discussing their earnings results in their Q4 Earnings Call to be held on February 26, 2018 at 4:30 PM Eastern ...
Today I will be providing a simple run-through of the discounted cash flows (DCF) method to estimate the attractiveness of Clovis Oncology Inc (NASDAQ:CLVS) as an investment opportunity. If youRead More...
Short interest is moderately high for CLVS with between 10 and 15% of shares outstanding currently on loan. The net inflows of $64 million over the last one-month into ETFs that hold CLVS are among the lowest of the last year and appear to be slowing.
Clovis Oncology is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
Clovis Oncology, Inc. announced today an update to the ongoing regulatory review for the Marketing Authorization Application for rucaparib tablets as monotherapy for the treatment of a limited population of advanced ovarian cancer patients with deleterious BRCA mutation .
Short interest is moderately high for CLVS with between 10 and 15% of shares outstanding currently on loan. The net inflows of $198 million over the last one-month into ETFs that hold CLVS are among the lowest of the last year and appear to be slowing.
Clovis Oncology, Inc. will announce its fourth quarter and full year 2017 financial results on Monday, February 26, 2018, after the close of the U.S. financial markets.
AstraZeneca's (AZN) PARP inhibitor, Lynparza, receives approval for treating ovarian cancer in Japan, following its label expansion in the United States.